BIONEWS
Run by the Broad Institute, Boston Children's, and Jackson Laboratory, a new non profit is asking FDA to treat one off rare disease gene therapy as a clinical procedure, not a separate drug approval.
A new non-profit is asking regulators to treat personalized rare-disease gene therapy like an organ transplant instead of a drug. Each case is built for one patient, so the cost math only works if the FDA agrees to handle it as a clinical procedure, not a separate drug approval for every individual treatment.
The Center for Therapeutic Genetics launched on Tuesday as a collaboration between the Broad Institute, Boston Children's Hospital, and Jackson Laboratory (JAX). The center is a non-profit, not a spinout, and it is built around an operating model closer to a clinical-trial network than a drug company: design and build precision medicines in-house, then hand the methods, data, and training to outside clinicians so they can replicate the work locally.
The comparison comes from founding director Winston Yan, a Broad Institute core member who has spent years developing bespoke gene-editing therapies for individual children with ultra-rare diseases. "We want to make personalized genetic treatments function more like clinical procedures, like organ transplants, where the hospital has the capability and you don't need a separate regulatory approval for each individual use," Yan told reporters at launch. The cost numbers explain why the comparison matters. Today's regulatory pathway forces each one-off treatment through its own FDA review, and that review is the structural reason a single custom therapy can run into seven-figure territory before a single dose is manufactured.
The "before" picture is the one rare-disease families already know. When a child has a mutation no commercial program is targeting, the family often ends up partnering with a single academic researcher, raising several million dollars through foundations and crowdfunding, and waiting years for an FDA green light. Each new patient restarts the cycle. Fewer than a handful of approved gene therapies address diseases this rare, and the families that reach the finish line tend to be the ones that can mobilize the most capital and the loudest advocates.
The Center for Therapeutic Genetics is built to compress that cycle by centralizing the technical stack: vector design (the engineered carrier that delivers the corrected gene), manufacturing protocols, regulatory templates, and a clinical network. In theory, a hospital in the network could take a delivery package, confirm the patient's variant, and run a known procedure rather than rebuilding the entire pipeline. Whether the FDA treats that delivery package the way it treats an organ-transplant protocol, with one master indication covering many uses, is the question that decides whether the model scales or stays a series of one-off miracles.
The policy handle to watch is the FDA's plausible-mechanism pathway, a framework the agency has begun using to accelerate bespoke gene-editing therapies by leaning on the mechanism of the editing tool rather than the specific disease target. The pathway is the closest existing foothold for the organ-transplant analogy, because it lets the agency clear a platform once and re-use that clearance for new indications. FierceBiotech and Inside Precision Medicine have both cast the launch as a bet that this pathway can be pushed further toward a clinical-procedure model.
The bet is non-trivial. The plausible-mechanism pathway is still a platform-indication approach, not a hospital-procedure approach, and it has not been used to clear a delivery package that outside clinicians can administer without a sponsor. Manufacturing cost is also a constraint the center will have to wrestle with in public: bespoke viral vectors and GMP-grade production remain the largest line items in any custom gene-therapy budget, and the center's cost-reduction claim depends on sharing those inputs across many patients. The launch press materials do not yet disclose a per-patient price target, and Yan has not committed to one.
The most concrete next signal is whether the center files any program under the plausible-mechanism pathway within its first twelve months, and whether the FDA accepts the filings. If it does, the organ-transplant analogy moves from launch line to operating reality. If the agency insists on per-patient filings, the non-profit will be running a faster version of the same bespoke-drug model it was built to replace.